Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use
NCT ID: NCT00799669
Last Updated: 2018-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
370 participants
OBSERVATIONAL
2007-12-05
2020-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized clinical trial is studying how well treatment to stop smoking and drinking works in preventing oral cancer in smokers in Puerto Rico.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Treatment for Tobacco and Alcohol Use
NCT00592085
Combined Treatment for Tobacco and Alcohol Use in Puerto Rico
NCT00570804
Mobile Smoking Cessation Intervention in Enhancing Cancer Outreach in Low-Income Adult Smokers
NCT00948129
Personalized Alerts and Care Pathways to Prompt Prevention Interventions for Alcohol and Tobacco Users in Primary Care
NCT03108144
Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit
NCT02905656
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To evaluate the effects of a motivational and problem-solving smoking cessation (MAPS) and a motivational and problem solving approach on at-risk alcohol use and smoking cessation (MAPS+) among Puerto Rican at-risk drinkers/smokers who call the Puerto Rico Quitline (PRQ).
* To assess effects of MAPS and MAPS+ on treatment mechanisms and the role of those mechanisms in mediating these effects on at-risk drinking and smoking cessation.
* To evaluate the cost-effectiveness of MAPS and MAPS+ in the reduction of at-risk drinking and smoking cessation.
OUTLINE: Minimization randomization is applied using the following variables: age, gender, cigarettes/day, number of drinks/day, and depression (score on the Center of Epidemiologic Studies Depression Scale). Patients are randomized to 1 of 2 intervention arms.
* Arm I (MAPS): Patients receive culturally sensitive self-help materials tailored for alcohol and tobacco users and 7 telephone counseling calls. The MAPS approach includes motivational interviewing and cognitive behavioral/problem-solving that focus on smoking cessation.
* Arm II (MAPS+): Patients receive culturally sensitive self-help materials tailored for alcohol and tobacco users and 7 telephone counseling calls. The MAPS+ approach includes motivational interviewing and cognitive behavioral/problems solving that focus on smoking cessation and the reduction of at-risk alcohol use.
In both arms, patients receive counseling calls over 15-30 minutes the week before quit date (QD), on QD, 3-5 days after QD, 7-10 days after QD, 15-30 days after QD, 45-60 days after QD, and on day 90 after QD. Patients complete questionnaires for alcohol- and smoking-related measures, self efficacy, stress/negative affects/depression, social support, and physical activity at baseline and weeks 12, 26 and 52 after QD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MAPS+
MAPS+ (Motivation and Problem-Solving Plus):
Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use.
smoking cessation intervention
Standard quit-smoking counseling to help decrease their risk of cancer.
counseling intervention
Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
preventive intervention
questionnaire administration
MAPS
MAPS (Motivation and Problem-Solving):
Counseling treatment approach with a focus on smoking cessation.
smoking cessation intervention
Standard quit-smoking counseling to help decrease their risk of cancer.
questionnaire administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
smoking cessation intervention
Standard quit-smoking counseling to help decrease their risk of cancer.
counseling intervention
Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
preventive intervention
questionnaire administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current daily smoker
* Called the Puerto Rico Quitline
* Motivated to quit smoking in the next 30 days
* Exhibits at least one of the following criteria for at-risk drinking:
* An average of ≥ 2 alcoholic beverages/day for men or ≥ 1 drink/day for women in the past 30 days
* Two or more occasions of consuming ≥ 5 alcoholic beverages/day for men or ≥ 4 drinks/day for women in the past 30 days
* Driving after consuming ≥ 3 drinks in the past 30 days
* Score of ≤ 15 on the Alcohol Use Disorders Identification Test
PATIENT CHARACTERISTICS:
* Not pregnant
* Residing in Puerto Rico
* Not currently incarcerated or in jail
* No other household member enrolled in this study
* Viable telephone number and home address
* Willing to provide the names, addresses, and phone numbers of up to 3 collaterals
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Wetter, PhD, MS, BA
Role: STUDY_CHAIR
M.D. Anderson Cancer Center
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Official Website
National Cancer Institute (NCI) Central Website for Cancer Research
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MDA-2005-0791
Identifier Type: -
Identifier Source: secondary_id
CDR0000626365
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-02110
Identifier Type: REGISTRY
Identifier Source: secondary_id
CDR0000626365
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.